Drug Trial Radar · NCT05269316
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
Feb 11, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Impact Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
Conditions
- Solid Tumor
- Advanced Solid Tumor
Interventions
IMP9064Drug
IMP9064 Monotherapy administered for 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (Safety and Tolerability)Time frame: 11 months
- To determine the Maximum Tolerable DoseTime frame: 11 months
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Hackensack University Medical Center PARTNER
Hackensack, New Jersey · Completed
Mount Sinai
New York, New York · Completed
Greenville Hospital System University Medical Center (ITOR)
Greenville, South Carolina · Completed
Mary Crowley Cancer Research Centers
Dallas, Texas · Completed
Linear Clinical Research Limited
Nedlands, Australia · Completed
Blacktown Hospital
Blacktown, New South Wales, Australia · Completed
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.